BMEA vs REKR Comparison

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Rekor Systems Inc is a roadway intelligence company focused on modernizing public safety, urban mobility, and transportation management through solutions. The company delivers services and solutions that collect, connect, and organize mobility data, providing real-time insights to support decision making, enhance situational awareness, enable rapid response, and support predictive analytics. The Company derives its revenues mainly from the licensing and sale of its roadway data and traffic management product and service offerings. These offerings include a mixture of data collection, implementation, engineering, customer support, and maintenance services, as well as software and hardware. The company operates in the United States and other regions.